AGOMAB IS LEVERAGING NEW SCIENTIFIC INSIGHTS AND ESTABLISHED DRUG DEVELOPMENT EXPERTISE TO DEVELOP POTENTIAL DISEASE-MODIFYING THERAPIES WITH WELL-VALIDATED TARGETS AND HIGH UNMET NEED
Fibrotic processes are the underlying factors in a variety of difficult-to-treat diseases, resulting in progressive organ failure. Agomab aims to resolve these processes through a broad focused pipeline of small molecule and antibody drug candidates designed for their unique and novel modes of actions against well-validated and potentially disease modifying targets, ultimately leading to repair of tissue injury, resolution of fibrosis and restoration of organ function.
We have a robust discovery pipeline including several programs in the early stages of development. Our most advanced preclinical asset is AGMB-101.
“We are focused on advancing our pipeline of proprietary product candidates in fibrotic diseases with the goal of bringing truly disease-modifying treatments to patients in need.”
Philippe Wiesel, Chief Medical Officer
